Strides Pharma Science Announcements
Intimation regarding Closure of Trading Window for Q2 and Half Year - FY26
25 Sep, 2025 | 02:57pm • Source: BSE
Strides'' Sustainability Report for FY25
24 Sep, 2025 | 11:01am • Source: BSE
2nd Reminder to Shareholders whose shares are due to be transferred to IEPF
19 Sep, 2025 | 06:02pm • Source: BSE
Schedule of Analyst/ Institutional Investors'' Meet
17 Sep, 2025 | 06:39pm • Source: BSE
Strides Enters into a Strategic Product Development Partnership with Kenox to Expand Nasal Spray Portfolio for the US Market
08 Sep, 2025 | 06:22pm • Source: BSE
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst/ Institutional Investor's Meet
26 Aug, 2025 | 05:36pm • Source: BSE
Deregistration of a non-operating step-down subsidiary of the Company in South Africa.
25 Aug, 2025 | 05:28pm • Source: BSE
Intimation regarding Voting Results and Scrutinizer Report of 34th Annual General Meeting of the Company
08 Aug, 2025 | 09:09pm • Source: BSE
We would like to inform you that Management of Strides will be attending investor conference organised by Emkay Global Financial Services Limited on August 12,...
07 Aug, 2025 | 08:25pm • Source: BSE
Proceedings of 34th Annual General Meeting of the Company
07 Aug, 2025 | 04:32pm • Source: BSE
Transcript of Earnings Call pertaining to unaudited financial results of the Company for the quarter ended June 30 2025
04 Aug, 2025 | 07:08pm • Source: BSE
Newspaper Advertisement- Unaudited Financial Results for the quarter ended June 30, 2025
30 Jul, 2025 | 06:01pm • Source: BSE
Allotment of shares under the ESOP Scheme
29 Jul, 2025 | 12:48pm • Source: BSE
Strides Pharma Science Limited has informed the Exchange regarding a press release dated July 29, 2025, titled "Strides Delivers a Strong Q1FY26 with ₹11,197m Revenue,...
29 Jul, 2025 | 12:48pm • Source: NSE
Strides Pharma Science Limited has informed the Exchange regarding Allotment of 10000 Shares
29 Jul, 2025 | 12:45pm • Source: NSE
Amendment to code of fair disclosure of UPSI
29 Jul, 2025 | 12:44pm • Source: BSE
Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025
29 Jul, 2025 | 12:42pm • Source: NSE
Strides Delivers a strong Q1 FY 2026 with Rs.11,197 million Revenue, Rs. 2,181 million EBITDA and Rs. 1,140 million Operational PAT.
29 Jul, 2025 | 12:41pm • Source: BSE
Allotment of Equity shares under the ESOP Scheme
29 Jul, 2025 | 12:37pm • Source: BSE
Financial Results (Consolidated & Standalone) for the quarter ended June 30, 2025
29 Jul, 2025 | 12:33pm • Source: BSE